Effect of continuous venovenous hemodiafiltration on darunavir and raltegravir exposure after administration via a gastroduodenal tube

AIDS

Volumn 25, Issue 10, 2011, Pages 1339-1341

  Taegtmeyer, Anne B ^a   Müller, Veronique ^a   Kovari, Helen ^a   Kullak Ublick, Gerd A ^a   Corti, Natascia ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CITALOPRAM; DARUNAVIR; ESOMEPRAZOLE; ETOPOSIDE; FOLIC ACID; LAMIVUDINE; LEVOTHYROXINE; RALTEGRAVIR; RITONAVIR; URSODEOXYCHOLIC ACID; VALGANCICLOVIR; VIRUS DNA; ZIDOVUDINE;

ADULT; ARTIFICIAL VENTILATION; ASCITES; CASE REPORT; CONTINUOUS HEMODIAFILTRATION; DRUG EXPOSURE; FEVER; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LETTER; LUNG INFILTRATE; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MALE; MULTIPLE ORGAN FAILURE; NASOGASTRIC TUBE; PLEURA EFFUSION; PRIORITY JOURNAL; RESPIRATORY FAILURE; SPLENOMEGALY; STOMACH TUBE; THROMBOCYTOPENIA; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; HEMODIAFILTRATION; HIV INFECTIONS; HUMANS; MALE; PYRROLIDINONES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 79958820077     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328347f40d     Document Type: Letter

References (14)

1. Oksenhendler E. HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS 2009; 4:16-21.
2. Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40:1559-1585. (Pubitemid 40720806)
3. Giguere P, la Porte C, Zhang G, Cameron B. Pharmacokinetics of darunavir, etravirine and raltegravir in an HIV-infected patient on haemodialysis. AIDS 2009; 23:740-742.
4. Bernard S BM, Bartoli M, Carron P, Stanke-Labesque F. Haemodialysis reduces raltegravir plasma concentrations. Nephrol Dial Transplant Plus 2010, 3:201-202.
5. Molto J, Sanz-Moreno J, Valle M, Cedeno S, Bonal J, Bouarich H, et al. Minimal removal of raltegravir by hemodialysis in HIV-infected patients with end-stage renal disease. Antimicrob Agents Chemother 2010; 54:3047-3048.
6. Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008; 83:293-299.
7. Prezista1 Product Monograph. Janssen-Cilag AG, Baar, Switzerland, 2010.
8. Isentress1 Product Monograph, Merck Sharp & Dohme-Chibret AG, Opfikon-Glattburg, Switzerland, 2009.
9. Petry AS, Wenning LA, Laethem T, De Smet M, Kost JT, Merschman S, et al. Safety, tolerability, and pharmacokinetics after single- and multiple-doses of MK-0518 in healthy subjects [Abstract]. 46th Interscience Conference onAntimicrobial Agents and Chemotherapy. 2006 San Francisco, abstract no. A-1424.
10. Bouman CS, van Kan HJ, Koopmans RP, Korevaar JC, Schultz MJ, Vroom MB. Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing. Intensive Care Med 2006; 32:2013-2019. (Pubitemid 44833115)
11. Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltra-tion in critically ill patients. Acta Anaesthesiol Scand 2001; 45:929-934. (Pubitemid 32912336)
12. Vermeir M, Lachau-Durand S, Mannens G, Cuyckens F, van Hoof B, Raoof A. Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects. Drug Metab Dispos 2009; 37:809-820.
13. Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, et al. Novel bis-tetrahydrofuranylurethane-containing non-peptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003; 47:3123-3129. (Pubitemid 37229567)
14. Cocohoba J, Dong BJ. Raltegravir: the first HIV integrase inhibitor. Clin Ther 2008; 30:1747-1765.